Loading...
Market
Which company will dominate the Alzheimer's treatment market in China by end of 2025?
2
Eli Lilly•China•National Medical Products Administration•Eisai•Biogen•Leqembi•United States•Japan•United Kingdom•South Korea
Resolution / Starting Odds
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%
Market research reports and sales data
Story
Eli Lilly's Donanemab Approved in China for Early Alzheimer's Treatment, Following Eisai and Biogen's January Approval
Dec 18, 2024, 01:56 AM
Eli Lilly's Alzheimer’s treatment, donanemab, has received approval from China's National Medical Products Administration for use in patients with early symptomatic Alzheimer's disease. This approval offers a new option for patients in China following the earlier approval of Eisai and Biogen's Leqembi in January. Donanemab has previously been authorized in the United States, Japan, and the United Kingdom, expanding its availability for those affected by the disease. The approval comes as a joint research team from South Korea and the U.S. has revealed insights into the mechanism by which tau proteins, linked to Alzheimer's, are removed from the brain.
View original story
Similar markets
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Avadel Pharmaceuticals • 25%
Jazz Pharmaceuticals • 25%
Another Company • 25%
No Dominant Player • 25%
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Merck • 25%
Roche • 25%
Another Pharmaceutical Company • 25%
No clear dominator • 25%